Glaxo opens court battle to defend Paxil patents against rival
Thursday 06 February 2003
GlaxoSmithKline has begun a vital US court battle to defend more than £1bn in annual sales of its most successful drug, the anti-depressant Paxil.
Lawyers for the pharmaceutical giant yesterday set out their arguments at the start of a trial in Chicago in which GSK alleges a smaller rival has infringed its patents.
Paxil sold in the UK as Seroxat had sales of £1.5bn in the first nine months of 2002, two-thirds of that in the US. An estimated 15 million Americans are treated for depression each year. The drug is also prescribed for panic attacks, anxiety, post-traumatic stress and obsessive compulsive disorder.
GSK is battling Apotex, a Canadian firm with plans to launch a subtly different version of the drug. Apotex says it either does not infringe GSK's patent on the main ingredient in Paxil, or that the patent which runs until December 2006 is not valid.
In trial papers, GSK says it could lose 80 per cent of its US sales of Paxil within weeks of a rival being launched. Investors fear a repeat of the disaster which befell Eli Lilly, the US giant, when its drug Prozac faced competitors in 2001. Prozac lost 70 per cent of its sales in a fortnight because doctors and medical insurers in the US demanded patients use the cheaper version.
The Apotex trial is seen as a guide to further trials elsewhere in the US against a slew of other companies with other versions of Paxil ready for launch. GSK's shares up 14p to 1,148p yesterday have lost a quarter of their value in a year, partly on fears that it could lose patent protection on Paxil. The company already faces a shortfall in earnings from next year because of a lack of new products to launch.
GSK is trying to increase sales of a new controlled-release version of Paxil, which has longer patent protection, before generic rivals become established.
- 1 Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
- 2 HeForShe campaign: Iceland to follow up Emma Watson speech with UN women's rights conference – for men only
- 3 Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
- 4 Teenagers irritable because early school hours mess with their biological clocks
- 5 Now we know whose fault it is if you end up being murdered in Thailand
Isis could become 'world’s first truly terrorist state' and bomb UK with nuclear and chemical weapons, Theresa May warns
Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
Car tax disc changes: Five facts you never knew about your (almost obsolete) tax disc
Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
Isis an hour away from Baghdad - with no sign of Iraq army being able to make a successful counter-attack
Isis, we are told, is a 'clear and dangerous threat to our way of life'. I’m sorry, but I just don’t buy it
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
The Osborne Ultimatum: Chancellor’s benefits freeze bombshell will affect ten million households
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Should gay sex be illegal? 16% of Britons think so
Mark Reckless becomes second Tory MP to defect to Ukip in a month
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...